BMC Infectious Diseases

Table 3 Sensitivity analysis

From: Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States

	Screening		No Screening
Treatment Rate w/o Screening	−50%	(±)50%	−50%	(±)50%
Cost^a	256,369,609	256,047,375	154,543,570	109,301,875
SAB	3	2	5	15
Pneumonia	3106	3061	16,769	10,486
PID	6574	5298	29,194	18,258
Neonatal Conjunctivitis	7321	6284	36,702	22,969
Vertical Transmission	9564	7495	45,777	28,537
Treated Chlamydia	470,462	541,354	83,781	244,898
Premature	3	2	7	4
Infertility	815	657	3620	2264
Cost of Chlamydia Screening
Cost^a	148,098,884	363,222,503	131,664,935	131,664,935

Outcomes of all endpoints when the values of high impact variables were varied over a range of +/-50% of base value
SAB spontaneous abortion, PID pelvic inflammatory disease
^aCosts expressed in 2015 USD

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com